The role of glimepiride in the effective management of Type 2 diabetes

被引:79
作者
Davis, SN [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA
关键词
diabetes; sulfonylureas; glimepiride; glucose;
D O I
10.1016/j.jdiacomp.2004.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions. The effective management of Type 2 diabetes is of vital concern to clinicians. The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention. The goals of pharmacologic therapy are to achieve adequate glycemic control while avoiding hypoglycemia and weight gain and to minimize the risk of future micro- and macrovascular complications. There are a number of available glucose-lowering agents from which to choose. This review focuses on the sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, which are effective, well-tolerated, and well-established drugs, Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, alpha-glucosidase inhibitors, and insulin. The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 70 条
[41]   Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control [J].
Matsumoto, K ;
Sera, Y ;
Abe, Y ;
Tominaga, T ;
Ueki, Y ;
Miyake, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (12) :1548-1552
[42]   SULFONYLUREA ANTIDIABETIC DRUGS - AN UPDATE OF THEIR CLINICAL-PHARMACOLOGY AND RATIONAL THERAPEUTIC USE [J].
MELANDER, A ;
BITZEN, PO ;
FABER, O ;
GROOP, L .
DRUGS, 1989, 37 (01) :58-72
[43]   SIMULTANEOUS ASSESSMENT OF INSULIN-SECRETION AND INSULIN SENSITIVITY USING A HYPERGLYCEMIC CLAMP [J].
MITRAKOU, A ;
VUORINENMARKKOLA, H ;
RAPTIS, G ;
TOFT, I ;
MOKAN, M ;
STRUMPH, P ;
PIMENTA, W ;
VENEMAN, T ;
JENSSEN, T ;
BOLLI, G ;
KORYTKOWSKI, M ;
YKIJARVINEN, H ;
GERICH, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :379-382
[44]   Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [J].
Mocanu, MM ;
Maddock, HL ;
Baxter, GF ;
Lawrence, CL ;
Standen, NB ;
Yellon, DM .
CIRCULATION, 2001, 103 (25) :3111-3116
[45]   DIFFERENTIAL INTERACTION OF GLIMEPIRIDE AND GLIBENCLAMIDE WITH THE BETA-CELL SULFONYLUREA RECEPTOR .1. BINDING CHARACTERISTICS [J].
MULLER, G ;
HARTZ, D ;
PUNTER, J ;
OKONOMOPULOS, R ;
KRAMER, W .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1994, 1191 (02) :267-277
[46]   The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro [J].
O'Brien, RC ;
Luo, M .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (12) :22-25
[47]   INSULIN-SECRETION IN DIABETES-MELLITUS [J].
PFEIFER, MA ;
HALTER, JB ;
PORTE, D .
AMERICAN JOURNAL OF MEDICINE, 1981, 70 (03) :579-588
[48]   Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes Influence of prior antidiabetic drug regimen [J].
Rendell, MS ;
Glazer, NB ;
Ye, Z .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (04) :211-217
[49]   Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients [J].
Riccio, A ;
Lisato, G ;
deKreutzenberg, SV ;
Marchetto, S ;
Turrin, M ;
Tiengo, A ;
DelPrato, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (10) :1196-1202
[50]  
Riddle M, 2001, DIABETES, V50, pA129